Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder

Journal of Clinical Psychiatry

Volumn 73, Issue 7, 2012, Pages

  Herring, W Joseph ^a   Wilens, Timothy E ^b   Adler, Lenard A ^c   Baranak, Christine ^a   Liu, Kenneth ^a   Snavely, Duane B ^a   Lines, Christopher R ^a   Michelson, David ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H3 RECEPTOR AGONIST; METHYLPHENIDATE; MK 0249; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CHRONIC DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ERECTILE DYSFUNCTION; FEMALE; HUMAN; INSOMNIA; IRRITABILITY; LABORATORY TEST; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MYDRIASIS; NERVOUSNESS; NEUROLOGIC EXAMINATION; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PILOT STUDY; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; URINARY DYSFUNCTION; VITAL SIGN; XEROSTOMIA;

EID: 84864413866     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m07178     Document Type: Article

References (40)

1. Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy. 2009;29(6):656-679. doi:10.1592/phco.29.6.656 PubMed
2. Faraone SV, Spencer T, Montano B, et al. Attention-deficit/hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care. Arch Intern Med. 2004;164:1221-1226. PubMed doi:10.101/archinte.164.1.121
3. Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2004;24(1):24-29. doi:10.1097/01.jcp.0108984.1879.95 PubMed (Pubitemid 38134162)
4. Mészáros A, Czobor P, Bálint S, et al. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol. 2009;12(8):1137-1147. doi:10.1017/S1461457090198 PubMed
5. Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs. 2009;23(suppl 1):21-31. doi:10.2165/023210-209230-04 PubMed
6. Tripp G, Wickens JR. Neurobiology of ADHD. Neuropharmacology. 2009;57(7-8):579-589. doi:10.1016/j.neuropharm.209.07.026 PubMed
7. Schwartz JC. Histaminergic mechanisms in brain. Annu Rev Pharmacol Toxicol. 1977;17(1):325-339. doi:10.146/anurev.pa.17.04017.01545 PubMed
8. Lin JS. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev. 2000;4(5):471-503. doi:10.1053/smrv.20.016 PubMed
9. Stocking EM, Letavic MA. Histamine H3 antagonists as wake-promoting and pro-cognitive agents. Curr Top Med Chem. 2008;8(11):988-1002. doi:10.2174/156802608784936728 PubMed
10. Gemkow MJ, Davenport AJ, Harich S, et al. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov Today. 2009;14(9-10):509-515. doi:10.1016/j.drudis.209.02.01 PubMed
11. Brioni JD, Esbenshade TA, Garrison TR, et al. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J Pharmacol Exp Ther. 2011;336(1):38-46. doi:10.124/jpet.10.16876. PubMed
12. Schwartz JC. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol. 2011;163(4):713-721. doi:10.1/j.1476-5381.201. 01286.x PubMed
13. Fox GB, Pan JB, Esbenshade TA, et al. Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav Brain Res. 2002;131(1-2):151-161. doi:10.1016/S016-4328(01)0379-5 PubMed (Pubitemid 34143166)
14. Nagase T, Mizutani T, Ishikawa S, et al. Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists. J Med Chem. 2008;51(15):4780-4789. doi:10.1021/jm803834 PubMed
15. Zoethout RW, Iannone R, Bloem BR, et al. The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol [published online ahead of print February 18, 2011]. J Psychopharmacol. 2012;26(2):292-302. PubMed
16. Iannone R, Palcza J, Renger JJ, et al. Acute alertness-promoting effects of a novel histamine subtype-3 receptor inverse agonist in healthy sleep-deprived male volunteers. Clin Pharmacol Ther. 2010;88(6):831-839. doi:10.1038/clpt.2010.205 PubMed
17. James LM, Iannone R, Palcza J, et al. Effect of a novel histamine subtype-3 receptor inverse agonist and modafinil on EEG power spectra during sleep deprivation and recovery sleep in male volunteers. Psychopharmacology (Berl). 2011;215(4):643-653. doi:10.107/s0213-010-2158-3 PubMed
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Press; 2000.
19. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):187-201. doi:10.1016/j.psc.203.12.03 PubMed (Pubitemid 38452762)
20. Conner CK, Erhardt D, Sparro E. Conners Adult ADHD Rating Scales (CAARS). New York, NY: Multi-Health Systems; 1999.
21. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
22. Spencer TJ, Adler LA, Meihua Qiao, et al. Validation of the Adult ADHD Investigator Symptom Rating Scale (AISRS). J Atten Disord. 2010;14(1):57-68. doi:10.17/1087054709347435 PubMed
23. Dyer FN. The Stroop Phenomenon and Its Use in the Study of Perceptual, Cognitive and Response Processes [# AD 749 451, 1972-06-07]. Springfield, VA: National Technical Information Service; 1972.
24. Conners CK, Epstein JN, Angold A, et al. Continuous Performance Test performance in a normative epidemiological sample. J Abnorm Child Psychol. 2003;31(5):555-562. doi:10.1023/A:102545730409 PubMed (Pubitemid 37229133)
25. Adler LA, Spencer T, Faraone SV, et al. Training raters to assess adult ADHD: reliability of ratings. J Atten Disord. 2005;8(3):121-126. doi:10.17/108705470527168 PubMed (Pubitemid 40805795)
26. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001;158(2):282-288. doi:10.176/api.ajp.158.2.282 PubMed (Pubitemid 32116526)
27. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829-835. doi:10.1016/j.biopsych.205.09.01 PubMed
28. Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol. 2009;29(3):239-247. doi:10.1097/JCP. 0b013e3181a390ce PubMed
29. Volkow ND, Wang GJ, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21(2):RC121. PubMed
30. Spencer T, Biederman J, Ciccone PE, et al. A PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short and long-acting oral methylphenidate. Am J Psychiatry. 2006;163:387-395. PubMed doi:10.176/api.ajp.163.3.387
31. Wilens TE, Gault LM, Childress A, et al. Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. J Am Acad Child Adolesc Psychiatry. 2011;50(1):73-84. e1. doi:10.1016/j.jac.2010.10.01 PubMed
32. Wilens TE, Klint T, Adler L, et al. A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. Behav Brain Funct. 2008;4(1):24. doi:10.186/174-9081-4-24 PubMed
33. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112-120. doi:10.1016/S06-323(02)01671-2 PubMed (Pubitemid 36126473)
34. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry. 2005;57(7):793-801. PubMed doi:10.1016/j.biopsych.205. 01.027
35. Faraone SV, Biederman J, Spencer T, et al. Atomoxetine and Stroop task performance in adult attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2005;15(4):664-670. doi:10.1089/cap.205.15.64 PubMed (Pubitemid 41434370)
36. Herring WJ, Hutzelmann J, Liu K, et al. Alerting and performance effects of the histamine inverse agonist MK-0249 in obstructive sleep apnea patients on CPAP with excessive daytime sleepiness: a randomized, controlled, adaptive crossover study [poster 219]. Presented at the SLEEP 2010 meeting of the American Academy of Sleep Medicine and the Sleep Research Society; June 7, 2010; San Antonio, TX. Sleep. 2010;33:abstract #0813.
37. Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics. 2005;116(6):e777-e784. doi:10.1542/peds.205-0617 PubMed (Pubitemid 46056456)
38. Cephalon Inc. Cephalon reports no benefit from Provigil [modafinil] in study of adults with ADHD. Cephalon news release: July 31, 2000. http://phx.corporate-ir.net/phoenix.zhtml?c=81709&p=irolnewsArticle&ID= 182727&highlight=. Verified March 15, 2012.
39. Pillot C, Héron A, Schwartz JC, et al. Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum. Eur J Neurosci. 2003;17(2):307-314. doi:10.1046/j.1460-9568.203.0242.x PubMed
40. Cho W, Maruff P, Connell J, et al. Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. Psychopharmacology (Berl). 2011;218(3):513-524. doi:10.107/s0213-01-234-y PubMed